Dr. Yi-Zhou Jiang is committed to the molecular subtyping and precision treatment of triple-negative breast cancer (TNBC). He has classified TNBCs into four molecular subtypes (the FUSCCTNBC subtyping system) to guide individualized treatment. He has established a “bench-to-bedside” research system that successfully translates basic research into novel clinical treatments and increases the objective response rate in patients with refractory metastatic TNBC from 10% to 29.8%. He has been funded by the National Natural Science Foundation Distinguished Youth Fund Project, the National Natural Science Foundation Outstanding Youth Fund Project, and the Project of the National Key R&D Program of China. In recent years, he has published 29 articles in renowned journals such as Cancer Cell, Science Translational Medicine, Cell Research, Nature Cancer, Nature Genetics, Lancet Oncology, Cell Metabolism, and Nature Chemistry as the corresponding author. His publications were cited a total of 6301 times. He has been honored with the First Prize of Shanghai Science and Technology Award, National Youth Post Expert, DAMO Academy Young Fellow, Shanghai Science and Technology Youth Elite Award, and the First Prize of the Shanghai Health System “Silver Snake Award”.
Yizhou Jiang
